Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$0.69
EPS est.
$0.61
EPS surprise
+12.20%
1-day move
-7.71%
Viatris reported an EPS that exceeded expectations, which is a positive sign for the company's profitability. However, the stock declined by 7.71% in reaction to the earnings report, indicating that investors may have been disappointed by the lack of revenue information or other factors not disclosed in the earnings call. The absence of guidance further adds to uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.69 | N/A | +12.20% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Viatris Inc. (VTRS) operates in the healthcare sector, focusing on pharmaceuticals. The company is significant as it provides a wide range of medications, including generic and specialty drugs, which are essential for patient care and public health.
Last quarter
In Q1-2026, Viatris reported an EPS of $0.59, exceeding expectations by 13.46%. The stock reacted positively, increasing by 9.03% the following day.
Management promises and guidance
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+7.53%
Avg 1-day reaction
+0.19%
Investors are cautiously optimistic ahead of the earnings report, hoping for continued EPS growth and stable revenue figures.
Bull case
If Viatris beats EPS expectations again, it could signal strong operational performance and boost investor confidence.
Bear case
A miss on earnings or lack of guidance could raise concerns about the company's growth trajectory and market position.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to last quarter's $0.59?
Given the strong EPS surprise last quarter, investors will be keen to see if this trend continues or if there are signs of a slowdown.
Q2
What is the company's outlook for revenue growth in the upcoming quarters?
Revenue growth is critical for sustaining investor confidence and assessing the company's market position.
—
Est. EPS
$3.08
Est. Rev
$7.2B
Impl. Move
±4.0%
Why consensus could be wrong
The Street may underestimate Viatris's ability to sustain its recent EPS growth due to strong demand for its generic drugs, which could lead to a surprise in earnings.
Supporting evidence
Viatris has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
The options market is pricing a larger move than historical averages, suggesting heightened expectations that could be unwarranted.
Key risk
If the EPS comes in below $0.55, it could undermine the positive sentiment and raise concerns about the company's growth trajectory.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it follows a strong surprise last quarter, setting high expectations for continued growth.
Bull confirmed if
An EPS of $0.60 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.55 would confirm the bear case, raising concerns about the company's growth potential.
What the market is pricing for the move.
Implied Move
±16.20%
Historical Avg
±8.7%
The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±16.2% while VTRS has averaged ±8.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
37.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
93.67%
of float
Insider
0.32%
of float
Holders
1,368
institutions
Top Holders· as of Jun 2026
FMR, LLC
96,662,102 sh · $1.7B
8.42%
482.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Viatris beats expectations, history suggests a potential stock increase of around 4.42%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors digest the commentary.
Miss
A miss could lead to a decline, with history suggesting an average drop of 15.21%, raising concerns about future growth.
The lines on the call that would change the story.
Blackrock Inc.
86,019,468 sh · $1.5B
7.49%
2.0%
Vanguard Capital Management LLC
76,046,939 sh · $1.3B
6.62%
1.8%
Davis Selected Advisers
75,232,254 sh · $1.3B
6.55%
-3.8%
Price (T.Rowe) Associates Inc
68,214,436 sh · $1.2B
5.94%
3.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.